It was discovered that pancreatic cancer patients had higher levels of DRD2 expression and that by blocking the extracellular regulated kinase signaling pathway, DRD2 inhibitors could decrease the growth of tumors [63,64]. This evidence concerns the gene DRD2 and pancreatic neoplasm.